Virpax Pharmaceuticals Navigates Stock, Governance, and Compliance Challenges

The latest announcement is out from Virpax Pharmaceuticals (VRPX).

Virpax Pharmaceuticals, Inc. has been given until September 30, 2024, to meet Nasdaq’s minimum stockholders’ equity requirement after falling short earlier in the year. At the company’s Annual Meeting, shareholders approved amendments to increase the number of shares available under the 2022 Equity Incentive Plan and the percentage of reserved shares for annual issuance. Additionally, Eric Floyd and Gary Herman were elected as directors, and EisnerAmper LLP was ratified as the independent accounting firm for the upcoming year.

See more insights into VRPX stock on TipRanks’ Stock Analysis page.